Mizuho lowered the firm’s price target on IN8bio (INAB) to $4 from $60 and keeps an Outperform rating on the shares. The firm continues to believe in IN8bio’s INB-100 program but adjusted the price target to reflect the 1-for-30 reverse stock split.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.